Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Ulf Gerdtham. Foto.

Ulf Gerdtham

Professor

Ulf Gerdtham. Foto.

Price indices of drugs and the switching to new drugs two empirical examples

Författare

  • Ulf-Göran Gerdtham
  • Magnus Johannesson
  • Bo Gunnarsson
  • Margareta Marcusson
  • Freddie Henriksson

Summary, in English

Standard price indices may not account for the price decrease that results when patients switch to pharmaceutical products for which their demand-reservation price exceeds the price of the new product. In a similar way, standard price indices may not account for the price increase that results when patients switch to pharmaceuticals for which the reservation price is below the price of the new drug. This study was designed to assess whether standard pharmaceutical price indices under- or overestimate the real price development resulting from new drug introductions. We illustrate that both situations may occur. In our first example, the switch from a branded to a generic drug, we showed that standard price indices recorded a price increase of about 16%, although the price actually decreased by about 5%. In our second example, the introduction of new formulation of a currently marketed drug, we showed that standard price indices recorded a price increase of about 6%, when the actual price increased by more than 65%.

Publiceringsår

1998-12-01

Språk

Engelska

Sidor

71-80

Publikation/Tidskrift/Serie

PharmacoEconomics

Volym

13

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Adis International

Ämne

  • Economics
  • Health Care Service and Management, Health Policy and Services and Health Economy

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1170-7690